Ophthotech Completes Patient Recruitment in Phase 3 Trial of Fovista® Anti-PDGF Therapy in Combination with Eylea® or Avastin® in Wet Age-Related Macular Degeneration
NEW YORK--(BUSINESS WIRE)--Ophthotech today announced the completion of patient recruitment in its Phase 3 trial of Fovista® for wet AMD, and that it has achieved a $30 million enrollment milestone from Novartis Pharma AG.
